Exact Sciences (EXAS) Competitors $54.05 +0.04 (+0.07%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. ALNY, BIIB, UTHR, INCY, NBIX, EXEL, BMRN, RGEN, HALO, and MDGLShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Is ALNY or EXAS more profitable? Alnylam Pharmaceuticals has a net margin of -12.37% compared to Exact Sciences' net margin of -37.29%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Exact Sciences -37.29%-5.29%-2.45% Do insiders and institutionals have more ownership in ALNY or EXAS? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to ALNY or EXAS? In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Exact Sciences. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 10 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.32 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ALNY or EXAS? Alnylam Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Does the MarketBeat Community favor ALNY or EXAS? Alnylam Pharmaceuticals received 174 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.34% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.14% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116876.34% Underperform Votes36223.66% Exact SciencesOutperform Votes99473.14% Underperform Votes36526.86% Do analysts prefer ALNY or EXAS? Alnylam Pharmaceuticals presently has a consensus price target of $319.58, suggesting a potential upside of 4.27%. Exact Sciences has a consensus price target of $70.90, suggesting a potential upside of 31.50%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Which has better earnings and valuation, ALNY or EXAS? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B17.02-$278.16M-$2.09-146.65Exact Sciences$2.83B3.60-$204.15M-$5.51-9.78 SummaryAlnylam Pharmaceuticals beats Exact Sciences on 10 of the 19 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.17B$3.12B$5.62B$8.58BDividend YieldN/A31.26%5.28%4.17%P/E Ratio-9.6814.2127.1919.81Price / Sales3.60179.01408.23154.60Price / Cash8.7957.5638.3234.64Price / Book4.174.796.994.65Net Income-$204.15M-$22.21M$3.23B$248.05M7 Day Performance-1.74%3.28%-0.18%-0.26%1 Month Performance0.46%6.35%8.61%4.37%1 Year Performance26.12%16.34%32.26%13.65% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.6137 of 5 stars$54.05+0.1%$70.90+31.2%+28.2%$10.20B$2.83B-9.716,400Positive NewsALNYAlnylam Pharmaceuticals4.2821 of 5 stars$304.00+1.1%$319.17+5.0%+91.6%$39.64B$2.35B-140.092,000Positive NewsAnalyst ForecastBIIBBiogen4.6876 of 5 stars$134.15+0.8%$191.30+42.6%-42.6%$19.66B$9.82B11.998,720Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9921 of 5 stars$328.40+0.8%$393.00+19.7%+1.5%$14.81B$2.99B14.42980Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionINCYIncyte4.5336 of 5 stars$69.89+1.6%$72.53+3.8%+15.5%$13.53B$4.41B258.862,320Positive NewsNBIXNeurocrine Biosciences4.8979 of 5 stars$125.73+0.3%$162.00+28.8%-7.1%$12.44B$2.41B38.221,200Analyst RevisionEXELExelixis4.5361 of 5 stars$42.92-0.3%$39.35-8.3%+89.4%$11.70B$2.30B24.251,220Positive NewsAnalyst ForecastBMRNBioMarin Pharmaceutical4.9518 of 5 stars$56.88+0.4%$93.45+64.3%-32.3%$10.91B$2.95B25.853,080Positive NewsAnalyst RevisionRGENRepligen4.8146 of 5 stars$131.68+2.6%$173.25+31.6%-8.1%$7.40B$650.43M-258.202,020HALOHalozyme Therapeutics4.9173 of 5 stars$54.38+0.2%$61.90+13.8%+9.8%$6.70B$1.08B15.85390MDGLMadrigal Pharmaceuticals4.3307 of 5 stars$280.24+0.7%$416.33+48.6%+4.0%$6.22B$317.38M-11.1790Positive NewsAnalyst RevisionGap Down Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts